Home|Journals|Articles by Year Follow on Twitter| Subscribe to List

Directory for Medical Articles

Open Access

Case Report

Ann Med Res. 2016; 23(3): 331-335

Glossodynia induced by panitumumab in metastatic colorectal cancer: report of two cases

Melek Karakurt Eryilmaz, Hasan Mutlu, Fatma Yalcin Musri, Gokhan Tazegul, Derya Kivrak Salim, Hasan Senol Coskun.

Colorectal cancer (CRC) is the third most common cancer, and is the third most common cause of death due to cancer in both women and men. Approximately 20 percent of patients with newly diagnosed colon cancer have distant metastatic disease at the time of diagnosis. Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), and it is commonly used to treat metastatic colorectal cancer (mCRC). Combinations of panitumumab plus an irinotecan or oxaliplatin-based regimen are reasonable both first-line and second-line options for mCRC with RAS wild type tumors. However, it has been associated with various side effects such as papulopustular acneiform rash, hypomagnesemia, and diarrhea. No previous reports on patients who developed tongue pain without stomatitis while treatment with panitumumab exists in the literature. Here we report two cases that developed tongue pain while on panitumumab for mCRC.

Key words: Panitumumab; Tongue Pain; Metastatic Colorectal Cancer.

Full-text options

Full-text Article



BiblioMed Home
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.